Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim Papp(Western University), Richard G. Langley(Dalhousie University), Mark Lebwohl(Icahn School of Medicine at Mount Sinai), Gerald G. Krueger(University of Utah), Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Ming-Chun Hsu, Yuhua Wang, Shu Li, Lisa T. Dooley, Kristian Reich(Dermatologikum Hamburg)
Cited by 1,348
Abstract
Related Papers
No related papers found
Powered by citation graph analysis